Print Page | Contact Us | Report Abuse | Sign In | Join
Latest Medical Marijuana News: COVID-19

Drug trial planned for synthetic cannabinoid coronavirus treatment

Thursday, June 25, 2020   (0 Comments)
Posted by: Elissa Rodrigues
Share |

A Philadelphia cannabis firm has joined the race to create a COVID-19 cure using cannabinoids. FSD Pharma, headquartered in Toronto, Canada, announced last week that the Food and Drug Administration (FDA) had approved the company’s application proposal to conduct clinical trials around the medicine. The treatment will use a drug called ultramicronized palmitoylethanolamid (or micro PEA) that includes synthetic molecules that mimic cannabinoids.

Micro PEA is a unique drug. It’s believed to act as an anti-inflammatory and promoted between 1969 and 1979 in former Czechoslovakia as treatment for influenza and the common cold. Clinical trials conducted at the time showed PEA was an effective prophylactic in respiratory infection, with no registered side effects. According to scientists behind the research, it could act as a quick therapeutic answer should a flu epidemic occur.

 

Today, the drug is promoted as a prescription nutraceutical in Italy and used to treat chronic inflammation. Pharmaceutical firm Epitech Group owned the rights to the drug and sold it under the names Normast and Pelvilen. Earlier this year, FSD purchased the worldwide rights from Epitech for $17.5 million and re-branded it as FSD-201.

 

"We contacted the FDA in late-March 2020 after becoming aware that several Italian physicians and scientists were advocating for use of ultramicronized PEA for patients suffering from symptoms of COVID-19, based on the drug's mechanism of action as a potent and safe anti-inflammatory agent that reduces the production of pro-inflammatory cytokines," Philadelphia-based physician and FSD CEO Raza Bokhari said in a statement.

 

In an interview with The Philadelphia Inquirer, Bokhari emphasized that FSD does not claim cannabinoids, synthetic or plant-based, is an alternative for COVID-19 treatment. But the CEO said FSD-201 modulates the endocannabinoid system as "a naturally occurring fatty acid" by targeting CB2 receptors, which are believed to affect pain and inflammation in humans.

 

"Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm," Bokhari told the Inquirer. "[FSD-201] is not a virus killer. But we believe it can mitigate that immune response, which can be fatal."

 

Previous research published in Preprints suggested marijuana could manipulate the main cellular gateway that COVID-19 enters the system. Researchers wrote that a novel combination of cannabinoids "may become a useful addition to the treatment of COVID-19." Israeli researchers have also launched clinical trials into whether marijuana terpenes could affect and/or prevent COVID-19.

 

The Fresh Toast is a daily lifestyle platform with a side of cannabis. For more information, visit www.thefreshtoast.com.

 

Source: Click here. 

Copyright 2020 The Fresh Toast.

Distributed by TRIBUNE CONTENT AGENCY, LLC.


 

Copyright © 2016-2020 American Medical Marijuana Physicians Association

Disclaimer: The American Medical Marijuana Physicians Association does not publish membership information. Our goal is to ensure that community physicians have the tools and resources they need to safely and effectively recommend medical marijuana as a last resort alternative treatment. Physicians should utilize this alternative recommendation based on evidence when available and always educate the patient on potential risks and other treatment options. The American Medical Marijuana Physicians Association supports the need for more research into cannabinoid medicine as more high quality studies are needed. By accessing any page on this site you agree to the Site Terms and Conditions of Use.